(firstQuint)Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure.

 This is an international, randomized, double-blind, placebo-controlled, Phase II/III trial of intravenous recombinant relaxin for the treatment of signs and symptoms in patients hospitalized for acute decompensated heart failure.

 The Phase II pilot study has completed; the Phase III main portion of the trial is ongoing.

.

 Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure@highlight

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure